Leerink Partners maintained a Market Perform rating on Impax Laboratories (NASDAQ: IPXL), and cut the price target to $47.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change Guidance

Impax Laboratories (IPXL) Misses Q2 EPS by 1cAugust 10, 2015 6:46 AM Impax Reports Second Quarter 2015 Financial ResultsAugust 10, 2015 6:45 AM Impax Laboratories (IPXL) Sells Daraprim U.S. Rights in $55M DealAugust 10, 2015 6:31 AM Impax Announces Sale of Daraprim® to Turing Pharmaceuticals AGAugust 10, 2015 6:30 AM Trading Radar for 8/10: Sysco (SYY), Dean Foods (DF), Take-Two (TTWO), Hertz Global (HTZ), ExOne (XONE) ReportAugust 7, 2015 2:39 PM